Marseille, France, September 18, 2017, 7:00 AM CEST
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 - IPH) today reports its consolidated financial results for the first half of 2017. The summary of the condensed half-year consolidated financial statements is attached to this press release.
During the period, Innate Pharma has continued to make significant progress across its portfolio of first-in-class clinical antibodies designed to harness the innate immune system.
In June 2017, Innate Pharma presented results from the dose-escalation part of the Phase I trial evaluating IPH4102 at the ICML[2]. The data reported suggest that IPH4102 is well tolerated and shows promising signs of clinical activity in elderly and heavily pretreated patients with advanced cutaneous T-cell lymphomas (CTCL), which is an orphan disease, mostly with Sézary syndrome, a subtype with high unmet medical need. Innate Pharma is currently working on the next steps of the clinical development plan for IPH4102 and will present updated data of the ongoing Phase I trial at the EORTC CLTF[3] meeting in London in October.
